These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Lieberman JA Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808 [No Abstract] [Full Text] [Related]
4. Pretrial medication bias in randomized antipsychotic drug trials. Leucht S; Heres S; Hamann J; Kissling W Am J Psychiatry; 2007 Aug; 164(8):1266; author reply 1266-7. PubMed ID: 17671291 [No Abstract] [Full Text] [Related]
5. Atypical antipsychotics and cognition in schizophrenia. Sharma T Arch Gen Psychiatry; 2002 Jun; 59(6):571-2; author reply 573-5. PubMed ID: 12044209 [No Abstract] [Full Text] [Related]
6. Should the CATIE study be a wake-up call? Ragins M Psychiatr Serv; 2005 Dec; 56(12):1489. PubMed ID: 16339608 [No Abstract] [Full Text] [Related]
7. Comparative effectiveness of antipsychotic drugs. Messori A Am J Psychiatry; 2003 Mar; 160(3):591-2; author reply 592-3. PubMed ID: 12611854 [No Abstract] [Full Text] [Related]
9. The CATIE study and its implications for antipsychotic drug use. Janicak PG Essent Psychopharmacol; 2006; 7(1):53-63. PubMed ID: 16989293 [No Abstract] [Full Text] [Related]
10. Lessons from each drug trial. Marder SR Am J Psychiatry; 2007 Mar; 164(3):375-6. PubMed ID: 17329457 [No Abstract] [Full Text] [Related]
11. Methodological concerns in a trial of ziprasidone and olanzapine. Carnahan RM; Perry PJ Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994736 [No Abstract] [Full Text] [Related]
13. A case study of SMART attributes: a qualitative assessment of generalizability, retention rate, and trial quality. Moodie EE; Karran JC; Shortreed SM Trials; 2016 May; 17(1):242. PubMed ID: 27180047 [TBL] [Abstract][Full Text] [Related]
14. The NIMH-CATIE Schizophrenia Study: what did we learn? Lieberman JA; Stroup TS Am J Psychiatry; 2011 Aug; 168(8):770-5. PubMed ID: 21813492 [No Abstract] [Full Text] [Related]
15. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Heinrichs RW Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745 [No Abstract] [Full Text] [Related]
16. Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent doses. Tandon R; Nasrallah HA Arch Gen Psychiatry; 2006 Aug; 63(8):935-7; author reply 937-9. PubMed ID: 16894070 [No Abstract] [Full Text] [Related]
17. Effectiveness of switching antipsychotic medications. Essock SM; Covell NH; Davis SM; Stroup TS; Rosenheck RA; Lieberman JA Am J Psychiatry; 2006 Dec; 163(12):2090-5. PubMed ID: 17151159 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK; Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466 [TBL] [Abstract][Full Text] [Related]
19. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Woods SW; Gueorguieva RV; Baker CB; Makuch RW Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728 [TBL] [Abstract][Full Text] [Related]
20. Risperidone and clozapine for treatment-resistant schizophrenia. Meltzer HY Am J Psychiatry; 1999 Jul; 156(7):1126-7; author reply 1127-8. PubMed ID: 10401484 [No Abstract] [Full Text] [Related] [Next] [New Search]